Skip to main content
| News

Escientia establishes subsidiary in the Basel Area

17.03.2021

The U.S. company Escientia Life Sciences Group has established a subsidiary in the canton of Basel-Landschaft. Escientia Switzerland will offer services to innovators and biotech startups at its Schweizerhalle facility.

Escientia's logo being assembled in Schweizerhalle (img: Escientia)

The new Escientia Switzerland subsidiary of the Escientia Life Sciences Group is based in Schweizerhalle, the industrial complex in the municipalities of Muttenz and Pratteln. The U.S. company offers services in the areas of drug discovery, development, production and commercialization. In the Getec Park in Schweizerhalle, Escientia has newly acquired a plant previously operated by Novartis. The investment and innovation promotion agency Basel Area Business & Innovation as well as the Standortförderung Baselland supported Escientia in establishing the subsidiary (read more about starting a business in Switzerland).

Escientia Switzerland will invest a two-digit million Swiss franc amount to modernize the plant and install manufacturing facilities for drug substance production. The 17,000 square meter site will then be providing services to large innovators and biotech startups in the Basel Area.

Alongside the various life sciences companies in the region that might be potential customers of Escientia, the U.S. company will also benefit from the highly qualified employees that the Basel Area has to offer. For this year alone, the creation of approximately 60 jobs is planned.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

KUORI developing biodegradable plastics
Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation, Invest, Sustainability

KUORI developing biodegradable plastics

The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...

Read More
Cell and gene therapies gain momentum in Basel
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Cell and gene therapies gain momentum in Basel

Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...

Read More
BLKB expanding support for startups
Basel Area Business & Innovation, Innovation, Invest

BLKB expanding support for startups

BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...

Read More
Combatting the rise of antimicrobial resistance
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Combatting the rise of antimicrobial resistance

Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...

Read More
AMR Action Fund invests in new antibiotics developed by BioVersys
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

AMR Action Fund invests in new antibiotics developed by BioVersys

The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...

Read More
Investors give Resistell 8.5 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Investors give Resistell 8.5 million Swiss francs

Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology...

Read More
1 2 3 31

Do you have a question? We'd like to hear from you.